Collegium Pharmaceutical

#5734

Rank

$863.38M

Marketcap

United States

Country

Leadership team

Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. (Co-Founder & Chairman)

Mr. Joseph J. Ciaffoni (Pres, CEO & Director)

Ms. Colleen Tupper (Exec. VP & CFO)

Products/ Services

Biotechnology, Life Science, Medical, Therapeutics

Number of Employees

100 - 500

Headquarters

Stoughton, Massachusetts, United States

Established

2002

Company Registration

SEC CIK number: 0001267565

Revenue

100M - 500M

Traded as

COLL

URL

https://www.collegiumpharma.com

Overview

Location

Recognition and Award

References

Summary

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

History

Collegium was founded in 2003 and is headquartered in Canton, Massachusetts. In 2012, Collegium completed a strategic partnership agreement with Covidien, now Mallinckrodt plc, to co-promote Xtampza® ER in the US. Xtampza ER is an oxycodone product utilizing Collegium’s patented DETERx oral abuse deterrent technology.

Mission

Our mission is to provide innovative solutions to address unmet medical needs. We will pursue innovative solutions to meet healthcare need, remain focused on the success of the patient, and sustain excellence in the development of medications.

Vision

Our vision is to become a leader in the development and commercialization of products by utilizing our proprietary DETERx platform technology.

Key Team

Ms. Shirley R. Kuhlmann (Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec.)

Mr. Scott Dreyer (Exec. VP & Chief Commercial Officer)

Dr. Richard Malamut M.D. (Exec. VP & Chief Medical Officer)

Ms. Alex Dasalla (Head of Investor Relations)

Mr. Bart J. Dunn (Exec. VP of Strategy & Corp. Devel.)

Ms. Marlo Manning (Head of HR)

Mr. Scott Sudduth (Head of Technical Operations)

Recognition and Awards

Collegium has won numerous awards since its founding, including the 2013 Massachusetts Innovation and Technology Exchange Award, two 2013 Frost & Sullivan Awards, and a New England Innovation Award in 2011.